arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RHYTHM PHARMACEUTICALS, INC.

RYTM
$99.30 ▲ +0.55 (+0.56%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
42 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RHYTHM PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.8B
Dividend Yield
Revenue Growth 46.9%
Op. Margin -68.1%
ROIC -24.9%
FCF / Share $-0.13
Trailing P/E
Price / Book 66.4x
FCF Yield
Debt / Equity 0.91
info Valuation on last close. End-of-day price, Sep 22, 2026.

42-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$71.25M
↑ +46.9%
Net Income Profit after all expenses
$-55.64M
↓ -12.4%
Operating Margin Operating profit as % of sales
-68.1%
↑ +21.8% 2th
FCF / Share Free cash flow per share
$-0.13
↑ +79.5%
Long-Term Debt Long-term obligations
$93.40M
↓ -5.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
5
Financial Health
39
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 42 quarters